<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492802</url>
  </required_header>
  <id_info>
    <org_study_id>POSA-CRP</org_study_id>
    <nct_id>NCT02492802</nct_id>
  </id_info>
  <brief_title>Effect of Inflammation on Pharmacokinetics of Posaconazole</brief_title>
  <official_title>Effect of Inflammation on Pharmacokinetics of Posaconazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Posaconazole plasma concentration and inflammatory markers will be determined in all samples
      available from routine analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective observational study will be performed at the University Medical Center
      Groningen, the Netherlands using longitudinal data collection. The design of the study will
      be that patients starting on posaconazole treatment will be evaluated. After informed consent
      is obtained medical data will be collected from the medical chart. Posaconazole plasma
      concentration (trough levels) and inflammatory markers (e.g. C-reactive protein) will be
      determined in all samples available from routine analysis (often daily). This will result in
      a detailed data set capturing day to day variations in inflammation and drug concentrations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2015</start_date>
  <completion_date type="Actual">August 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>posaconazole plasma concentration (mg/L)</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>posaconazole drug exposure during treatment in different stages of inflammation</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">65</enrollment>
  <condition>Mycoses</condition>
  <arm_group>
    <arm_group_label>posaconazole-group</arm_group_label>
    <description>patients receiving posaconazole for prophylaxis or treatment of invasive fungal infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>posaconazole</intervention_name>
    <description>collection plasma samples for measuring posaconazole drug concentration</description>
    <arm_group_label>posaconazole-group</arm_group_label>
    <other_name>noxafil</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  patients with hematological malignancies

          -  immunocompromised patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 yrs

          -  receiving posaconazole

          -  Written informed consent

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Willem Alffenaar, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2015</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Jan-Willem C Alffenaar</investigator_full_name>
    <investigator_title>PharmD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 7, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

